10-QPeriod: Q2 FY2020

DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2020

Filed July 28, 2020For Securities:DXCM

Summary

DexCom, Inc. reported strong financial performance for the six months ended June 30, 2020, with total revenue increasing by 39% to $856.9 million compared to the same period in the prior year. This growth was primarily driven by increased sales volume of their disposable sensors, reflecting continued customer base expansion. The company also achieved significant improvements in gross profit, which rose by 44% to $540.6 million, with gross margin expanding to 63% from 61% in the prior year. This was attributed to higher revenues and cost savings from manufacturing efficiencies, although partially offset by charges related to manufacturing process shifts and COVID-19 related costs. Financially, DexCom demonstrated a substantial improvement in profitability, moving from a net loss of $37.4 million in the first six months of 2019 to a net income of $66.2 million in the same period of 2020. This turnaround is reflected in the earnings per share, which improved from a loss of $0.41 per share to earnings of $0.71 per share on a basic basis. The company also significantly strengthened its balance sheet, with cash, cash equivalents, and marketable securities increasing by $975.5 million to $2.51 billion as of June 30, 2020, largely due to proceeds from the issuance of senior convertible notes. Management expressed confidence that current liquidity and cash flow generation are sufficient to meet anticipated needs for at least the next 12 months.

Financial Statements
Beta
Revenue$451.80M
Cost of Revenue$167.70M
Gross Profit$284.10M
R&D Expenses$79.90M
SG&A Expenses$136.40M
Operating Expenses$216.30M
Operating Income$67.80M
Interest Expense$20.30M
Net Income$46.30M
EPS (Basic)$0.12
EPS (Diluted)$0.12
Shares Outstanding (Basic)375.20M
Shares Outstanding (Diluted)388.00M

Key Highlights

  • 1Revenue increased by 39% year-over-year to $856.9 million for the first six months of 2020, driven by strong sensor sales volume.
  • 2Gross profit grew 44% to $540.6 million, with gross margin improving to 63% due to increased revenue and manufacturing efficiencies.
  • 3The company achieved profitability, reporting a net income of $66.2 million for the first six months of 2020, a significant improvement from a net loss of $37.4 million in the prior year.
  • 4Basic earnings per share improved to $0.71 from a loss of $0.41 in the comparable prior period.
  • 5Cash, cash equivalents, and marketable securities significantly increased to $2.51 billion as of June 30, 2020, bolstered by a large convertible note issuance.
  • 6Operating expenses increased, with R&D up 20% and SG&A up 9% for the six-month period, reflecting investments in growth and increased marketing/consulting costs.
  • 7The company successfully managed a $5.4 million loss on extinguishment of debt related to the repurchase and conversion of its 2022 senior convertible notes.

Frequently Asked Questions

The primary driver of DexCom's revenue growth was the increased sales volume of their disposable sensors, reflecting the continued expansion of their global customer base.

While COVID-19 presented challenges such as potential disruptions to new patient additions due to stay-at-home orders, DexCom also saw benefits from the shift to telemedicine and increased demand for their real-time connectivity for virtual diabetes care and patient monitoring in hospitals. The company incurred incremental costs for safety precautions and IT infrastructure but indicated that accumulated costs did not present a material impact on their financial liquidity or position.

DexCom has outstanding senior convertible notes due in 2022, 2023, and 2025. The company repurchased a portion of its 2022 notes and redeemed the remainder, with holders having the option to convert them before redemption. The significant issuance of 0.25% Senior Convertible Notes due 2025 in May 2020 provided substantial proceeds.

DexCom's liquidity position significantly improved, with cash, cash equivalents, and short-term marketable securities increasing by $975.5 million to $2.51 billion as of June 30, 2020. This increase was largely attributable to the net proceeds from the issuance of its 2025 senior convertible notes.